Market Scope

Market Research Future (MRFR) studied the global overactive bladder treatment market 2021 in the review period till 2023. As per MRFR daat, the Overactive Bladder Treatment Market is expected to thrive at 3.1% CAGR during the forecast tenure (from 2022 to 2028). By 2023, the global overactive bladder treatment market is expected to earn decent value.

Market Drivers and Restraints

The rise in the number of patients with urinary urgency and high frequency, and nocturia; typically diagnosed with overactive bladder (OAB) can boost the need for effective treatment. The rise in occurrences of neurological diseases, especially among the growing geriatric group, can prompt the need for OAB management that can support the expansion of the global OAB market in the assessment period. In addition, upgradation and innovations of intravesical therapies and rapid commercialization of such new launches by pharma companies can prompt the market rise in the assessment tenure.

On the other hand, issues with funding new solutions and identification of undesired systemic effects can hinder the OAB market growth in the evaluation period.

Key Players

Astellas Pharma Inc., Pfizer, Inc., Allergan, Plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Endo International Plc, Sanofi S. A., Aurobindo Pharma Limited, Intas Pharmaceuticals Ltd., Johnson & Johnson, Apotex Inc., Medtronic PLC, Macleods Pharmaceuticals Ltd., and Cogentix Medical, Inc., are some top-notch companies that are operating in the overactive bladder treatment market as listed by MRFR.

Segment Assessment

The segment assessment of the global overactive bladder treatment market is based on non-pharmacological treatment, pharmacotherapy, and disease.

The pharmacotherapy-based segments of the overactive bladder treatment market are anticholinergics, neurostimulation, Botox, and mirabegron among others. The anticholinergics segment studies solifenacin, fesoterodine, oxybutynin, tolterodine, darifenacin, and trospium among others. The segment of anticholinergic is expected to earn considerable profit due to the high efficacy of treatment. In addition, the availability of numerous types of anticholinergics that are compatible with all body types can favor the market. 

The non-pharmacological treatment-based segments of the global Overactive Bladder Treatment Market are behavioral therapy, dietary and fluid modifications, and pelvic floor muscle rehabilitation among others. The adoption of non-pharmacological treatments due to its non-invasive nature and growing preference among patients can underpin the rise of the OAB market. Behavioral therapy is gaining prominence among people, hence the behavioral therapy segment is likely to thrive in the assessment period. 

The disease-based segments of the OAB market are neurogenic overactive bladder and idiopathic overactive bladder. The neurogenic overactive bladder segment studies OAB in Parkinson's disease, the overactive bladder in stroke, OAB in spinal cord injury, and the overactive bladder in several other disorders. The growing cases of overactive bladder caused due to neurological issues can cause the segment to rise in the assessment period. The increase in number of patients that are reported for overactive bladder due to Parkinsonism can add to the market upsurge. The hike in count of stroke cases can prompt the market rise in the analysis period.

Regional Analysis

The market of overactive bladder treatment is assessed across the Americas, Asia Pacific, Europe, and the Middle East and Africa. In North America, the overactive bladder treatment is expected to thrive at a considerable pace owing to expansion of geriatric populace and rise in incidences of urinary and OAB incontinence symptoms. In addition, the introduction of healthcare coverage systems, such as; Medicare can add to the rise of the market in the Americas . According to the data by National Association for Continence (NAFC), around 25 million Americans adults experience chronic urinary incontinence and transients. The range is around 75 to 80% for women suffering from overactive bladder. In Europe, the market of overactive bladder looks lucrative. The rise in occurrences of OAB and hike in healthcare expenditure are causes that are likely to prompt the market in the assessment period. In Asia Pacific, the availability of affordable reimbursement options can aid the regional OAB market to surge. The increase in cases of OAB among geriatric population, along with rise in cognizance of its modern treatment can prompt APAC market in the review tenure. The existence of robust medical setup and launch of initiatives taken by APAC governments to support medical attention for the middle class population can favor the regional OAB market. In the Middle East region and Africa, the overactive bladder treatment market can witness sluggish growth owing to socio-political backwardness.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America